Riociguat
Soluble Guanylate Cyclase Stimulator — CARDIOVASCULAR SYSTEM
Also known as: adempas, BAY 63-2521
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Riociguat is an ofp drug in the Soluble Guanylate Cyclase Stimulator class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Guanylate Cyclase Stimulators. DrugCentral lists 2 molecular targets, including GUCY1B3 and PDE7B. Recorded indications include Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.
- Approval status: ofp (first approved 2013 by the FDA).
- Drug class: Soluble Guanylate Cyclase Stimulator.
- Mechanism of action: Guanylate Cyclase Stimulators.
- Molecular targets: GUCY1B3 and PDE7B (2 listed in DrugCentral).
- Indications: Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.
- ATC code: C02KX05 (Antihypertensives for pulmonary arterial hypertension).
- Molecular formula: C20H19FN8O2; molecular weight 422.42 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
Contraindications (1)
- Pregnancy, function
Mechanism & targets
| Mechanism of action (MoA) | Guanylate Cyclase Stimulators |
|---|---|
| Established pharmacologic class | Soluble Guanylate Cyclase Stimulator |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Guanylate cyclase soluble subunit beta-1 | GUCY1B3 | positive allosteric modulator | MEC 7.52 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 7B | PDE7B | unknown | IC50 5.54 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2013-10-08 | FDA | — | BAYER HLTHCARE | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C02KX05 | CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Death | 2839.6 |
| Hospitalisation | 2683.5 |
| Dyspnoea | 1919.3 |
| Fluid retention | 1758.7 |
| Hypotension | 1542.2 |
| Dyspnoea exertional | 1458.5 |
| Pain in jaw | 1189.9 |
| Pulmonary arterial hypertension | 1172.9 |
| Headache | 1090.7 |
| Dizziness | 886.4 |
| Pulmonary hypertension | 774.6 |
| Right ventricular failure | 755.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Riociguat is on its molecule page.
| Molecular formula | C20H19FN8O2 |
|---|---|
| Molecular weight | 422.42 g/mol |
| CAS number | 625115-55-1 |
| InChIKey | WXXSNCNJFUAIDG-UHFFFAOYSA-N |
| PubChem CID | 11304743 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Riociguat used for?
DrugCentral lists the following indications for Riociguat: Chronic thromboembolic pulmonary hypertension and Pulmonary arterial hypertension.
How does Riociguat work?
Riociguat is classified as Guanylate Cyclase Stimulators; its molecular targets in DrugCentral include GUCY1B3 (positive allosteric modulator) and PDE7B.
When was Riociguat first approved?
Riociguat was first approved by the FDA in 2013.
What drug class does Riociguat belong to?
Riociguat is in the Soluble Guanylate Cyclase Stimulator class.
What is the chemical formula of Riociguat?
Riociguat has the molecular formula C20H19FN8O2 and a molecular weight of 422.42 g/mol.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4807 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2107834 — compound record and bioactivity
- PubChem CID 11304743 — chemical identifiers
- DrugBank DB08931 — drug record
- FDA UNII RU3FE2Y4XI — substance identity
- DailyMed: FDA labels for Riociguat — current prescribing information (label search)
- UniProt Q02153 (GUCY1B3) — target protein
- UniProt Q9NP56 (PDE7B) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.